8-K/A: Protagenic Amends 8-K/A for Auditor Consent

Protagenic Therapeutics, Inc. filed an amendment to its Form 8-K/A to update the auditor's consent related to the Phytanix Bio acquisition.

Summary

• Protagenic Therapeutics, Inc. (PTIX) filed an Amendment No. 2 to its Current Report on Form 8-K/A.
• This amendment specifically updates Exhibit 23.1, which is the Consent of GreenGrowth CPAs Inc.
• The original Form 8-K/A, filed on August 28, 2025, included financial statements and pro forma financial information for the acquisition of Phytanix Bio.
• The acquisition of 100% of Phytanix Bio occurred on May 15, 2025, as previously reported on May 19, 2025.
• GreenGrowth CPAs Inc. provided consent for the inclusion of their audit report for Phytanix Bio's consolidated balance sheets as of March 31, 2025, and 2024, and related statements for the periods then ended.
• No other changes were made to the original Form 8-K/A.

Sentiment

Score: 5

Explanation: Neutral, as this is an administrative filing to update an auditor's consent, not a performance or strategic announcement.

Key Dates

Recommendation

This filing is an administrative amendment to include an auditor's consent for previously filed financial statements related to an acquisition. It does not contain new financial performance data, strategic updates, or material events that would alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as there's no new information to warrant a change in position.

Keywords

Protagenic Therapeutics, PTIX, SEC filing, 8-K/A, Phytanix Bio, acquisition, auditor consent, GreenGrowth CPAs, financial statements, corporate governance